Equitable Trust Co. grew its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,060 shares of the medical research company’s stock after acquiring an additional 132 shares during the period. Equitable Trust Co.’s holdings in Amgen were worth $497,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the company. Wealth Quarterback LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $3,116,210,000. Johanson Financial Advisors Inc. increased its stake in Amgen by 24,240.9% in the 4th quarter. Johanson Financial Advisors Inc. now owns 1,216,801 shares of the medical research company’s stock valued at $5,052,000 after buying an additional 1,211,802 shares during the last quarter. CI Investments Inc. grew its position in shares of Amgen by 890.2% in the 4th quarter. CI Investments Inc. now owns 370,823 shares of the medical research company’s stock valued at $89,394,000 after acquiring an additional 333,372 shares during the period. Annex Advisory Services LLC grew its position in shares of Amgen by 3,053.0% in the 4th quarter. Annex Advisory Services LLC now owns 322,046 shares of the medical research company’s stock valued at $3,548,000 after acquiring an additional 311,832 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Amgen by 109.0% in the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 554,768 shares of the medical research company’s stock valued at $133,738,000 after acquiring an additional 289,346 shares during the period. Institutional investors and hedge funds own 77.36% of the company’s stock.
Shares of NASDAQ:AMGN traded down $0.28 during midday trading on Thursday, hitting $192.86. The stock had a trading volume of 16,603 shares, compared to its average volume of 4,565,924. The company’s 50-day moving average price is $211.45 and its 200-day moving average price is $218.00. The company has a market capitalization of $119.34 billion, a P/E ratio of 15.15, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11. The company has a quick ratio of 1.16, a current ratio of 1.44 and a debt-to-equity ratio of 2.79. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $244.99.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $3.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.47 by $0.17. The business had revenue of $6.20 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.42 EPS. Research analysts expect that Amgen, Inc. will post 15.55 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 8th. Investors of record on Monday, May 18th will be given a dividend of $1.60 per share. This represents a $6.40 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 43.18%.
In other Amgen news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $233.72, for a total transaction of $99,331.00. Following the sale, the director now directly owns 4,988 shares of the company’s stock, valued at approximately $1,165,795.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Piacquad sold 9,264 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $229.93, for a total transaction of $2,130,071.52. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.
AMGN has been the subject of several research analyst reports. Oppenheimer reduced their target price on shares of Amgen from $250.00 to $240.00 and set an “outperform” rating for the company in a report on Thursday. UBS Group lifted their target price on shares of Amgen from $194.00 to $238.00 and gave the stock a “neutral” rating in a report on Wednesday, January 22nd. Raymond James initiated coverage on shares of Amgen in a report on Monday, December 23rd. They set a “market perform” rating for the company. Cfra raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, March 13th. Finally, ValuEngine upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $237.91.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Index Funds
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.